UniQure's Huntington's gene therapy reportedly showed less benefit after four years than after three in a small trial
Bloomberg reports UniQure said AMT-130's benefits in a small trial were not as good after four years as after three. Barron's reports the company still sees a path to approval, even as its stock plunged 48%.
TLDR
Bloomberg reports UniQure said the benefits of its experimental Huntington's gene therapy, AMT-130, were not as good after four years as after three in a small trial. Bloomberg says the result could complicate its bid for US approval. Barron's reports UniQure still sees a path to regulatory approval, even as its stock plunged 48%.
Combined views
27.4K
2 Sources, first seen 3h ago